Adjuvant #melanoma phase 2 of pembro +/- individualized neoantigen therapy (mRNA-4157/V940; KEYNOTE-942) The Lancet! Excited to be part of this trial & helping to lead on-going Ph3 (NCT05933577). Just might be the next big thing for cancer in general...
sciencedirect.com/science/articl…

DKN-01 Plus Bevacizumab and Chemotherapy Shows Tolerability, Activity in MSS CRC @meredithpelster Sarah Cannon Docs @asco #GI24 #crcsm
onclive.com/view/dkn-01-pl…

We are thrilled to announce SCRI Oncology Partners! With this expansion of the SCRI network, we build upon our capabilities and will undertake new groundbreaking studies that will continue our mission to advance cancer care.
usoncology.com/news/the-us-on…

7th AIM at Melanoma Foundation Women in Melanoma #WIM meeting. Absolutely my favorite meeting of the year- these women are such role models to me and have shaped my career in countless ways. Sunandana Chandra, MD Janice Mehnert, MD Pauline Funchain Bella Glitza, MD, PhD Sapna Patel Katy Tsai, MD

Ocular Melanoma A Cure In Sight July 22 Seminar join us for up to date discussion on therapeutics. HonorHealth Research Institute The Angeles Clinic Sarah Cannon Docs Meredith McKean MD, MPH Lauren A. Dalvin, MD Mayo Clinic Department of Ophthalmology Immunocore Foghorn Therapeutics Castle Biosciences
acureinsight.org/education-even…

Drug companies Moderna and Merck have released encouraging results from a vaccine trial that shows promise in the battle against Stage 3 and Stage 4 melanoma, the most serious type of skin cancer. Dr. Natalie Azar breaks down the findings.

Dr. Danso moderated this afternoon’s #ASCO23 metastatic breast cancer session where Erika Hamilton, MD delivered exciting data on a phase 2 HER3-Dxd study Daiichi Sankyo #VirginiaOncologyAssociates

Melissa L. Johnson w excellent presentation of ARC-7: RP2 of Domvanalimab (antiTIGIT) Zimberelimab (antiPD1) v Zim in 1L PDL1H NSCLC in ASCO Plenary Rapid Updates. PFS - HR
0.67 (0.4, 1.13) Sarah Cannon Docs #ASCO23 #LCSM

Dr. Erika Hamilton, MD takes the #ASCO23 stage to present data from adjuvant monarchE trial.

Heading to #ASCO23 ? Join us for a MasterClass and Case Forum on next-gen immunotherapies in #melanoma on June 3. Get all the details and register today for this 6/3 6:30 PM CDT live event with Jason Luke, MD, FACP, Meredith McKean MD, MPH, & Dr. Kendra: bit.ly/2023Melanoma #OncoTwitter

We are pleased to welcome Dr. Ishwaria Subbiah to the SCRI network where she will lead two critical programs to further advance our mission for both our patients and research care teams. Learn more about her new role:
sarahcannon.com/about/newsroom…

NEW on the #eyebelievepodcast for #mentalhealthawarenessmonth - Dr. Sanger, a licensed psychologist at Tennessee Oncology, discusses strategies for protecting your mental health as an OM patient. Share and subscribe on your listening platform! apple.co/3I5yzAT

Don't miss the sign up for an exciting webinar! Tune in on Monday, May 15th for expert advice on clinical trials. Register now at the link below (it will be recorded and shared on the podcast later this month!)

tinyurl.com/clinicaltrials…

Today, we are pleased to announce Dr. Vivek Subbiah, MD, a globally recognized key opinion leader in precision medicine and early-phase research, will be joining the SCRI team. Learn more about his new role and contributions to drug development: 
lnkd.in/eg43drvg

Exciting news! The FDA approved a treatment combination based on the POSEIDON Phase III Trial results. Read more about this #NSCLC treatment and Melissa L. Johnson’s response in the press release.

Neoadjuvant #melanoma PD1+LAG3 trial nature Impressive data, correlative analysis & practice changing level set for neoadj #immunotherapy in peri-surgical dz. Great work by many esp Dr Amaria Michael Postow Jennifer Wargo MD Charlotte Ariyan Hussein Tawbi, MD, PhD
nature.com/articles/s4158…

Proud of the work we do for first in human (FIH) drug development ⁦Sarah Cannon Docs⁩.

Congrats ⁦Benjamin Garmezy 🎉

Janux Therapeutics Announces 1st Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer pharmaceuticaldaily.com/janux-therapeu…

Improving distant metastasis free survival & updated relapse-free survival for anti-PD1 in stage IIB/C #melanoma from KN716 - just in time for #SMR22 ! Hope all are enjoying Edinburgh! The Lancet Oncology Society Melanoma Res
authors.elsevier.com/c/1fxC65EIIgI0…

In her session this morning, ⁦Meredith McKean MD, MPH⁩ speaks to advances in the field while sharing her #scsm22 presentation, “Eye on the Prize: Progress in Cutaneous and Uveal Melanoma.”

Dr. Garmezy rocking his first Sarah Cannon annual meeting presentation this morning- exciting GU research updates Benjamin Garmezy #scsm22